Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Don't wait for the heart attack. A new analysis of the VESALIUS-CV trial finds that evolocumab (Repatha), a PCSK9 inhibitor, reduces all-cause mortality in high-risk patients who haven't yet had an MI or stroke — not just cardiovascular deaths. Researchers believe the drug prevents a "domino effect" where cardiac events lead to frailty, making patients less able to survive infections or cancer.
Don't wait for the heart attack. A new analysis of the VESALIUS-CV trial, presented at the ESC Congress 2026 and published in Circulation, shows that the PCSK9 inhibitor evolocumab (Repatha) reduces all-cause mortality in high-risk patients who have never had an MI or stroke — not just cardiovascular deaths. The survival benefit emerged after about 1.5 years of treatment and was consistent across both CV and non-CV death categories.
So how does a cholesterol drug reduce deaths from infections and cancer? Researchers believe it's an indirect "domino effect": by preventing major cardiac events, evolocumab keeps patients from becoming frail, making them more resilient when facing other serious illnesses. Lead author Dr. Robert Giugliano emphasized that the benefit likely applies to any potent lipid-lowering therapy, not just PCSK9 inhibitors specifically.
By the Numbers:
Why it matters: Editorialists caution that these findings don't justify prescribing evolocumab to every high-risk patient, but they do challenge the clinical norm of waiting for a first cardiac event before aggressively treating lipids. Access barriers — including cost, prior authorizations, and insurance gaps — remain significant hurdles to translating this survival benefit into real-world practice.
